newsfilter
← Latest News
PR Newswire·

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...